Benjamin F. Edwards & Company Inc. Has $359,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Posted by on Jul 18th, 2023

Benjamin F. Edwards & Company Inc. lowered its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 3.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,259 shares of the company’s stock after selling 79 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Novo Nordisk A/S were worth $359,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Schubert & Co grew its holdings in Novo Nordisk A/S by 96.2% during the 4th quarter. Schubert & Co now owns 204 shares of the company’s stock worth $28,000 after acquiring an additional 100 shares during the last quarter. Tsfg LLC bought a new stake in Novo Nordisk A/S during the 4th quarter worth about $30,000. RFP Financial Group LLC bought a new stake in Novo Nordisk A/S during the 4th quarter worth about $30,000. Worth Asset Management LLC bought a new stake in Novo Nordisk A/S during the 1st quarter worth about $32,000. Finally, Ahrens Investment Partners LLC bought a new stake in Novo Nordisk A/S during the 1st quarter worth about $36,000. Institutional investors own 6.30% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of research analyst reports. HSBC started coverage on shares of Novo Nordisk A/S in a report on Friday. They set a “buy” rating on the stock. Credit Suisse Group raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Thursday, April 13th. Finally, StockNews.com started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 18th. They issued a “strong-buy” rating on the stock.

Novo Nordisk A/S Stock Up 0.6 %

Shares of NYSE NVO opened at $161.03 on Tuesday. The stock has a market cap of $361.31 billion, a P/E ratio of 42.38, a P/E/G ratio of 1.44 and a beta of 0.47. The firm has a 50 day moving average price of $161.24 and a 200 day moving average price of $152.75. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.67 and a current ratio of 0.86. Novo Nordisk A/S has a 52-week low of $95.02 and a 52-week high of $172.97.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its quarterly earnings data on Thursday, May 4th. The company reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. The firm had revenue of $7.69 billion during the quarter, compared to analysts’ expectations of $7.86 billion. Novo Nordisk A/S had a net margin of 32.53% and a return on equity of 77.39%. Analysts expect that Novo Nordisk A/S will post 5.07 EPS for the current year.

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.

Featured Articles

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.